{"id":"oxynorm-capsules","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"15-25","effect":"Drowsiness"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Pruritus"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone works by activating mu-opioid receptors throughout the brain and spinal cord, which modulates pain perception and emotional response to pain. The immediate-release capsule formulation allows rapid onset of analgesia, making it suitable for acute pain management and breakthrough pain in opioid-tolerant patients.","oneSentence":"OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:19.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"},{"name":"Breakthrough pain in opioid-tolerant patients"}]},"trialDetails":[{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT01643772","phase":"PHASE1","title":"OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2011-05","conditions":"Pain","enrollment":61},{"nctId":"NCT03314792","phase":"PHASE4","title":"Effects of Tapentadol Versus Oxycodone After Hysterectomy.","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-12-04","conditions":"Pain, Postoperative, Pain Uterus, Pain, Acute","enrollment":86},{"nctId":"NCT01675635","phase":"PHASE3","title":"OxyNorm Capsules in Post-Operative Pain Study","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2011-07","conditions":"Postoperative Pain","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OxyNorm"],"phase":"phase_3","status":"active","brandName":"OxyNorm Capsules","genericName":"OxyNorm Capsules","companyName":"Mundipharma (China) Pharmaceutical Co. Ltd","companyId":"mundipharma-china-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OxyNorm is an immediate-release oral formulation of oxycodone, a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects. Used for Moderate to severe acute pain, Breakthrough pain in opioid-tolerant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}